Patent attributes
The present invention relates to a method to identify substances and a use of such substances which can modulate IL-4 dependent signaling involved in tumor diseases, preferably Hodgkin Lymphomas or inflammatory airway diseases, preferably asthma and a method for determining whether a substance can modulate the interaction of STAT6 with NCoA-1, characterized in thata) STAT6 or fragments or derivatives thereof having the ability to bind to NcoA-1 are brought into contact with NCoA-1 or fragments or derivatives of NCoA-1 having the ability to bind STAT6 under conditions where STAT6 and NCoA-1 or fragments or derivatives thereof are capable of forming a complex, and the complex can be used to induce a measurable readout;b) a readout is measured in the absence or presence of the substance of interest;c) the readout in absence of substance of interest is compared with readout in presence of substance of interest.
